Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | ACP3 | P15309 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8849605 | 0.68 | DDB1 (0.53) | DDB1CRBNADRA1APDPK1SIGMAR1 | |
| SCHEMBL3255766 | 0.68 | DDB1 (0.38) | DDB1CRBNADRA1APDPK1ADRA2B | |
| SCHEMBL6561469 | 0.68 | DDB1 (0.34) | DDB1CRBNPDPK1HTR2C | |
| SCHEMBL3248563 | 0.67 | DDB1 (0.37) | DDB1CRBNADRA1APDPK1ADRA2B | |
| SCHEMBL9710611 | 0.67 | ADRA1A (0.36) | DDB1CRBNSRD5A1ADRA1APDPK1 | |
| SCHEMBL9430604 | 0.67 | ADRA1A (0.40) | SRD5A1ADRA1APDPK1ACP3SIGMAR1 | |
| SCHEMBL17910084 | 0.67 | TP53 (0.39) | DDB1CRBNHTR2AHTR2C | |
| SCHEMBL28806293 | 0.66 | ADRA1A (0.49) | ADRA1APDPK1SIGMAR1IDO1 | |
| SCHEMBL14247675 | 0.66 | ADRA1A (0.49) | ADRA1APDPK1SIGMAR1IDO1 | |
| SCHEMBL11767850 | 0.66 | PRCP (0.56) | ADRA1APDPK1SIGMAR1GID4IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1175383-B1 | GLUCOCORTICOID RECEPTOR MODULATORS | PFIZER PROD INC (US) | 2018-03-14 | — | — | EP | disclosed |
| EP-1521733-B1 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR | PFIZER PROD INC (US) | 2014-08-20 | — | — | EP | disclosed |
| US-7713989-B2 | Glucocorticoid receptor modulators | DOW ROBERT L | 2010-05-11 | — | — | US | disclosed |
| US-20090215908-A1 | TOLL LIKE RECEPTOR (TLR) SIGNALING ANTAGONIST | RELIANCE LIFE SCIENCES PVT. LTD. (IN) | 2009-08-27 | — | — | US | disclosed |
| US-7553877-B2 | Use of 2-hydroxy-1,2,3,4,4a,9,10,10a-octahydrophenanthrene compounds glucocorticoid receptor agonists to treat certain inflammatory conditions such as arthritis, asthma | PFIZER, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| WO-2009047791-A2 | TOLL LIKE RECEPTOR (TLR) SIGNALING ANTAGONIST | RELIANCE LIFE SCIENCES PVT. LTD. (IN) | 2009-04-16 | — | — | WO | disclosed |
| US-20070117805-A1 | Glucocorticoid receptor modulators | PFIZER INC. | 2007-05-24 | — | — | US | disclosed |
| US-7166593-B2 | Glucocorticoid receptor modulators | PFIZER, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-7138406-B2 | Antiinflammatory agents; antiallergens; vision defects; anticancer agents; gastrointestinal disorders | PFIZER, INC. (US) | 2006-11-21 | — | — | US | disclosed |
| US-20060247264-A1 | Use of 2-hydroxy-1,2,3,4,4a,9,10,10a-octahydrophenanthrene compounds glucocorticoid receptor agonists to treat certain inflammatory conditions such as arthritis, asthma | PFIZER INC | 2006-11-02 | — | — | US | disclosed |
| US-20040176595-A1 | Glucocorticoid receptor modulators | PFIZER, INC. | 2004-09-09 | — | — | US | disclosed |
| US-20040138262-A1 | Antiinflammatory agents; antiallergens; vision defects; anticancer agents; gastrointestinal disorders | PFIZER INC. | 2004-07-15 | — | — | US | disclosed |
| US-6699893-B2 | DIETETICS; ANTIDIABETIC AGENTS; ANTIINFLAMMATROY AGENTS | PFIZER INC | 2004-03-02 | — | — | US | disclosed |
| US-20040014741-A1 | Glucocorticoid receptor modulators | LIU KEVIN K (US) | 2004-01-22 | — | — | US | disclosed |
| WO-2004005229-A1 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR | PFIZER PRODUCTS INC. (US) | 2004-01-15 | — | — | WO | disclosed |
| US-20020147336-A1 | Glucocorticoid receptor modulators | DOW ROBERT L (US) | 2002-10-10 | — | — | US | disclosed |
| US-20020107235-A1 | Glucocorticoid receptor modulators | LIU KEVIN K (US) | 2002-08-08 | — | — | US | disclosed |
| EP-1201649-A1 | Glucocorticoid receptor modulators | Pfizer Products Inc. (US) | 2002-05-02 | — | — | EP | disclosed |
| EP-1201660-A1 | Glucocorticoid receptor modulators | Pfizer Products Inc. (US) | 2002-05-02 | — | — | EP | disclosed |
| US-6380223-B1 | FOR THERAPY OF DISEASES, SUCH AS OBESITY, DIABETES, INFLAMMATION | PFIZER INC. | 2002-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176595-A1 | Glucocorticoid receptor modulators | NR3C1, NR3C2, MC2R | DDB1 3100/4885CRBN 3203/4885SRD5A1 98/4885 |
| US-20060247264-A1 | Use of 2-hydroxy-1,2,3,4,4a,9,10,10a-octahydrophenanthrene compounds glucocorticoid receptor agonists to treat certain inflammatory conditions such as arthritis, asthma | NR3C1, NR3C2, LTB4R2 | DDB1 3002/4885CRBN 3761/4885SRD5A1 37/4885 |
| US-20090215908-A1 | TOLL LIKE RECEPTOR (TLR) SIGNALING ANTAGONIST | TLR4, TLR5, TLR1 | DDB1 1804/4885CRBN 3984/4885SRD5A1 2634/4885 |
| US-20040138262-A1 | Antiinflammatory agents; antiallergens; vision defects; anticancer agents; gastrointestinal disorders | NR3C1, MC2R, FPR1 | DDB1 1022/4885CRBN 1176/4885SRD5A1 56/4885 |
| US-20040014741-A1 | Glucocorticoid receptor modulators | NR3C1, NR3C2, MC2R | DDB1 3737/4885CRBN 3490/4885SRD5A1 94/4885 |
| US-20020147336-A1 | Glucocorticoid receptor modulators | NR3C1, NR3C2, MC2R | DDB1 3053/4885CRBN 3182/4885SRD5A1 99/4885 |
| US-20020107235-A1 | Glucocorticoid receptor modulators | NR3C1, NR3C2, MC2R | DDB1 3711/4885CRBN 3409/4885SRD5A1 93/4885 |
| US-20070117805-A1 | Glucocorticoid receptor modulators | NR3C1, NR3C2, MC2R | DDB1 3113/4885CRBN 3166/4885SRD5A1 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.